The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

According to the company the compound could potentially be the world’s first US Food and Drug Administration (FDA) approved ...

This article evaluates the currently used treatment regimens in ocular anti-VEGF therapy for exudative age-related macular degeneration. Anti-VEGF therapies using variable injection regimens and ...

FT Global Pharma and Biotech Summit 2024. Credit: Irena Maragkou ...

Allovir Inc., which has struggled since late last December, will merge with privately held Kalaris Therapeutics Inc. to develop therapies for treating neovascular and exudative retinal diseases.